ArticleEpilepsia open2025
Cognitive outcomes after deep brain stimulation in drug-resistant epilepsy: A comparison of anterior thalamic and hippocampal stimulation.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveDeep brain stimulation (DBS) of the anterior thalamic nucleus (ATN) and hippocampus is an emerging therapy for drug-resistant epilepsy (DRE) when resective surgery is not feasible. We aimed to evaluate the long-term cognitive outcomes of these two DBS targets, hypothesizing that both interventions preserve cognitive function.
methodsWe conducted a retrospective analysis of DRE patients who underwent ATN-DBS (n = 12) or hippocampal DBS (n = 10) and completed comprehensive neuropsychological testing before surgery and after ≥18 months of stimulation. Testing assessed general cognition, intellectual function, memory, language, and executive function. Changes in performance (post- minus pre-DBS) were analyzed within each group and between groups, with appropriate correction for multiple comparisons.
resultsAt median follow-ups of 44.33 months (ATN-DBS) and 28.60 months (Hip-DBS), both groups achieved comparable seizure reductions, particularly for disabling seizures (ATN-DBS: 73.05%; Hip-DBS: 76.76%). No significant cognitive decline was observed in either group across any domain. After FDR correction, no cognitive measure showed significant change (p > 0.05 for all). Unadjusted comparisons revealed modest improvement trends in visuospatial reasoning with ATN-DBS (Perceptual Reasoning Index, p = 0.047 uncorrected) and semantic verbal fluency with hippocampal DBS (p = 0.041 uncorrected), but these did not remain significant after correction. Between-group comparisons identified no significant cognitive differences. SIGNIFICANCE: ATN and hippocampal stimulation demonstrated comparable efficacy for seizure control while maintaining cognitive stability over long-term follow-up. Despite targeting key structures in memory and cognitive networks, neither approach produced measurable cognitive deterioration. These findings provide critical reassurance regarding the cognitive safety of DBS in epilepsy and suggest that target selection can prioritize optimizing seizure control without compromising cognitive function. PLAIN LANGUAGE SUMMARY: This study compared cognitive outcomes in patients with difficult-to-treat epilepsy who received deep brain stimulation (DBS) in one of two brain regions: the anterior thalamic nucleus or the hippocampus. Both treatments effectively reduced seizures by over 70%. Importantly, after 2-4 years of continuous stimulation, neither treatment caused any decline in thinking abilities such as memory, language, nor problem-solving - despite targeting brain regions critical for these functions. This provides reassurance that DBS represents a cognitively safe option for epilepsy patients who cannot undergo traditional surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.